Business
Spectral to present at Rodman & Renshaw Annual Global Investment Conference on September 13
TORONTO, Sept. 6, 2011 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI) , a Phase III company d...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\n\nTORONTO, Sept. 6, 2011 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI), a Phase III company developing the first theranostic treatment for\n patients with septic shock, today announced that Dr. Paul Walker, the\n Company's President Chief Executive Officer, will present at the\n Rodman Renshaw Annual Global Investment Conference.\n\n\nDr. Walker will discuss Spectral's lead theranostics product that\n combines the EAA™ diagnostic with the Toraymyxin therapeutic, the\n progress of its U.S. Phase III pivotal trial, which is the world's\n first theranostics trial in the area of sepsis, and the upcoming\n milestones for the Company. More than 250,000 patients are diagnosed\n with severe sepsis and septic shock in the U.S. each year, representing\n a greater than $1 billion market opportunity for Spectral.\n\n\nWHEN: Tuesday, September 13, 2011 at 4:30 pm (Eastern Time)\n\n\nWHERE: Starlight South room, The Waldorf=Astoria hotel in New York\n\n\nAn archived version of the PowerPoint will be available following the\n presentation at the Company's website.\n\n\nFor additional information on the conference please visit:\n\n\nhttp://www.rodmanandrenshaw.com/conferences?id=162\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment for severe sepsis and septic\n shock. Toraymyxin is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared\n diagnostic for the risk of developing sepsis. Spectral's EUPHRATES\n trial is the world's first theranostics trial in the area of sepsis.\n\n\nToraymyxin has been approved for therapeutic use in Japan and Europe,\n and has been used safely and effectively in more than 80,000 patients\n to date. In March 2009, Spectral obtained the exclusive development and\n commercial rights in the U.S. for Toraymyxin, and in November 2010,\n signed an exclusive distribution agreement for this product in Canada.\n More than 250,000 patients are diagnosed with severe sepsis and septic\n shock in North America each year, representing a greater than $1\n billion market opportunity for Spectral. Spectral is listed on the\n Toronto Stock Exchange under the symbol SDI. For furthe...